Catalyst Biosciences Inc., of South San Francisco, disclosed a reverse stock split of its shares of common stock at a ratio of 1-for-15, effective Friday. Shares will begin trading on a split-adjusted basis on Monday, and the number of shares of Catalyst's common stock outstanding will decrease from about 13 million pre-split shares to about 868,000 post-split shares.